PROK PROKIDNEY CORP

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025

WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present two posters, including a late-breaking poster on the Phase 2 REGEN-007 study results, at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held from November 6-9, 2025, in Houston, TX.

The titles for the accepted abstracts are provided below and accessible online at:

Late-Breaking Poster Presentation

Renal Autologous Cell Therapy in Diabetes and CKD (Phase 2 REGEN-007 Study Results)

Session Title: Late-Breaking Science Posters [LB-PO]

Session Date, Time: November 6, 2025 from 10:00 AM to 12:00 PM CST

Poster Board #: TH-PO1203

Other Poster Presentation

Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel

Session Title: Development, Stem Cells, and Regenerative Medicine [PO0600]

Session Date, Time: November 6, 2025 from 10:00 AM to 12:00 PM CST

Poster Board #: TH-PO0575

Following the event, a copy of the poster presentations will be available on the Company’s website at:

Additional information on ASN Kidney Week 2025 can be accessed online at:

About ProKidney Corp.

ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit .

ProKidney Contact

Ethan Holdaway

Media Contact

Audra Friis 

Investor Relations Contact

Daniel Ferry



EN
20/10/2025

Underlying

PROKPROKIDNEY CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PROKIDNEY CORP

 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Reports Third Quarter 2025 Financial Results and Provides Re...

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the patients required for the Phase 3 REGEN-006 (PROACT 1) accelerated approval analysis using estimated glomerular filtration rate (eGFR) slope have been enrolled; topline results anticipated in Q2 2027Ended the third quarter with $272 million in cash and cash equivalents and marketable securities,...

November 10, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Ri...

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral kidney injection with rilparencel resulted in a 4.6 mL/min/1.73m2 (78%) improvement in the annual decline of estimated glomerular filtration rate (eGFR) slope in Group 1 (n=24) patientsNo rilparencel-related serious adverse events were observed; the overall study sa...

November 6, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healt...

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in November: Guggenheim Healthcare Innovation Conference (Boston)Date: Wednesday, November 12, 2...

October 29, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Announces Two Abstracts Selected for Presentation at the Ame...

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025 WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present two posters, including a late-breaking poster on the Phase 2 REGEN-007 study results, at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held from November 6-9, 2025, in Houston, TX. The tit...

October 20, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney to Participate in Two Upcoming Conferences: the Citi Biophar...

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in September: Citi Biopharma Back to School Conference (Boston)Date:Wednesday, September ...

August 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch